vorasidenib
servier,agios pharma
['vorasidenib', 'agiospharma']
#vorasidenib, acquired from in a $1.8 billion deal, slowed the growth of a certain type of low-grade glioma by 61% in a phase iii trial.
#vorasidenib #agiospharma #pharmaceuticals #biospace 
Your source for biopharma news and jobs